GSK unlocks data on more drug studies; Merck inks $172M pain drug discovery deal;

@FierceBiotech: PR: PharmAthene, Theraclone announce merger agreement to create #biologics co. targeting gov't and commerical markets. More | Follow @FierceBiotech

@JohnCFierce: Interesting to see Astra's Q2 report highlights late-stage deals. That took awhile. Makes a better case for near-term turnaround potential. | Follow @JohnCFierce

@RyanMFierce: Good time in biotech to find $: Karyopharm Therapeutics Secures $19 Million in Series B Financing Extension. Release | Follow @RyanMFierce

@EmilyMFierce: From FierceBiotechResearch.com: La Jolla, Kyowa Hakko Kirin partner on autoimmune disease drug discovery. Story | Follow @EmilyMFierce

> GSK ($GSK) officials say they plan to double the number of studies which will be open for qualified researchers to inspect by the end of this year. The pharma giant is committed to revealing all the data it has on approved drugs or terminated projects dating back to 2000. Story

> Australia's Bionomics has struck a $172 million deal with Merck ($MRK) to discover and develop novel small molecule candidates for the treatment of chronic pain, including neuropathic pain. Release

Medical Device News

@FierceMedDev: Thoratec's revenue keeps rising, fueled by HeartMate sales. How long can the surge last? More | Follow @FierceMedDev

@MarkHFierce: Smith & Nephew can thank emerging markets, in part, for steady Q2 growth. More from Bloomberg | Follow @MarkHFierce

@DamianFierce: KKR is buying another CRO, planning to merge RPS with PRA once the transactions close. Report | Follow @DamianFierce

> Hansen eyes $93M, bigger share of robotic surgery market. News

> Covidien watches profits slide after kicking drugs. More

> How long can HeartMate pump Thoratec's revenue? Article

Pharma News

@FiercePharma: Wishful thinking or prophecy? Sanofi Q2 release titled "Last Quarter with Significant Negative Impact from the Patent Cliff." | Follow @FiercePharma

@CarlyHFierce:  Price controls in #India triggering confusion for companies and consumers alike. Item | Follow @CarlyHFierce

> Tension rises in China as officials fine J&J, visit Sanofi. News

> Gist of AstraZeneca's Q2 results: It could have been worse. More

Pharma Manufacturing News

> Fresenius cans managers tied to data manipulation. Article

> CEO says Hospira is making progress on manufacturing fixes. Report

> India's price controls trigger labeling confusion. Item

> European gene-therapy pioneer to expand manufacturing with U.S. plant. News

Vaccines News

> Sanofi, MedImmune begin shipping flu vaccines. Item

> National action plans needed to stop hepatitis B, WHO says. Story

> GSK, Pfizer commit more vaccines to Unicef program. Article

> CDC: U.S. 'dropping the ball' on HPV vaccinations. More

And Finally... Researchers say that the incidence of peripheral artery disease has risen quickly in recent years. Patients suffering from PAD are at risk of heart attacks, strokes and an early death. Story

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.